Get more information on Digital Diabetes Management Market - Request Free Sample Report
The Digital Diabetes Management Market Size was valued at USD 18.8 billion in 2023, and is expected to reach USD 59.7 billion by 2032, and grow at a CAGR of 13.7% over the forecast period 2024-2032.
The market's rapid rise can be attributed to the rising prevalence of diabetes as well as technical advancement and innovation. As digital technology advances, the diabetes industry is projected to see a wide range of technologies that have the potential to revolutionize the way we manage the condition. Over the last few years, the number of smartphone apps accessible for illness management has expanded, and there are over a hundred apps available on web-based app stores that can help patients monitor their blood glucose levels. Rapidly changing lifestyles, such as smoking and alcohol usage, are contributing to an increase in the number of diabetes patients globally. Furthermore, obesity is one of the key risk factors for diabetes. With an increasing obese population and increased patient awareness, the market for diet and weight control apps is showing great promise.
Diabetes is a medical disorder in which the pancreas' inability to make insulin results in a rise in blood glucose levels. Diabetic patients encounter numerous daily obstacles, such as determining what to eat, comprehending medical advice, and recognizing the influence of food and activities on blood sugar levels. Patients can address their health issues by engaging with the healthcare team and sharing data because digital technology is available at any time and from any location. This is a digital ecosystem of data-driven technologies that will connect patients and their care teams for better diabetes control.
DRIVERS
Artificial Intelligence Is Making Its Way Into Diabetes Care Devices
Artificial intelligence (Al) is a rapidly expanding field, and its applications in diabetes have revolutionized the approach to the diagnosis and management of this chronic condition. Machine learning principles have been utilized to generate algorithms to provide predictive models for the risk of getting diabetes or its complications. Technological advancements have aided in the optimization of diabetes resource consumption. These astute technical modifications have resulted in improved glycemic control, including decreases in fasting and postprandial glucose levels, glucose excursions, and glycosylated hemoglobin.
Al will offer a paradigm shift in diabetes care, moving away from traditional management tactics and toward the development of tailored, data-driven precision care. Livongo Health (United States), for example, is employing a big-data-driven strategy to assist people in managing their health and improving their lifestyles. Many individuals use the company's unique devices, which include blood glucose meters, blood pressure cuffs, and scales that can collect data and communicate it to a larger database. The organization then uses this data to generate complete insights for the benefit of patients.
RESTRAIN
High equipment costs and a lack of reimbursement in poor countries
OPPORTUNITY
Increasing diabetes-related health-care spending
Diabetes-related worldwide health expenditure has increased significantly, rising from USD 236 billion in 2007 to USD 966 billion in 2021 for adults aged 20 to 80 years. This reflects a 318% growth rate over the previous 15 years. A portion of this rise can be attributable to better data quality. Diabetes' direct expenditures are projected to rise further. According to the IDF Atlas 2021, overall diabetes-related health spending will reach USD 1.04 trillion by 2030 and USD 1.07 trillion by 2045. The North America and Caribbean region has the largest diabetes-related health spending per adult diabetic (USD 8,209), followed by Europe (USD 3,088), South and Central America (USD 2,190), the Western Pacific (USD 2,191), and the WP region (1,206 USD). This amount is USD 465 per diabetic person in the Middle East and North Africa region, USD 548 in Africa, and USD 112 in Southeast Asia. Diabetes expenditure has a significant impact on total health expenditure worldwide, accounting for 11.6% of total global health spending. Given the rising cost of diabetes-related health care in developing nations, several digital diabetes management device makers are focusing on growing their presence in these areas in order to capitalize on new opportunities.
CHALLENGES
In emerging economies, penetration is low
Uncertainty in the Market Geopolitical unrest may wreak havoc on financial markets and undermine investor confidence. This could result in lower spending on healthcare and technology, including digital diabetes management. Regulatory Difficulties Following a significant conflict, regulatory frameworks in impacted regions may change, potentially affecting the approval, distribution, and use of medical devices, including digital diabetes management solutions. Economic Impact Wars and conflicts can cause economic downturns in the countries involved and abroad. Reduced purchasing power and higher healthcare expenditures as a result of the war's aftermath may affect both demand for and affordability of digital diabetes control options. Prioritize Immediate needs. During a crisis, healthcare resources may be diverted to more pressing issues, such as treating war-related injuries and providing emergency medical care. This may divert attention away from the development and implementation of digital diabetes management systems.
IMPACT OF ONGOING RECESSION
During the study period, 680 individuals had their blood pressure measured at least once a year, and 274 had their HbA1c measured at least once a year. Because only 58 patients had a recorded BMI at least once a year, the cohort was confined to all patients with at least one recorded BMI per time period (pre-recession, recession, and post-recession), resulting in a BMI trend sample of 1,021 individuals. Mean changes in HbA1c and BP from one year to the next, as well as mean changes in BMI between time periods, were investigated while accounting for repeated assessments. HbA1c levels steadily decreased over the whole study period. Prior to the recession, blood pressure had been declining on a yearly basis.
By Product
Smart Glucose Meter
Continuous Blood Glucose Monitoring System
Smart Insulin Pens
Smart Insulin Pumps
Apps
Digital Diabetes Management Apps
Weight & Diet Management Apps
By Type
Wearable Devices
Handheld Devices
By End Use
Hospitals
Home settings
Diagnostic Centers
REGIONAL ANALYSES
North America will have the greatest CAGR in the digital diabetes management market in 2023, followed by Europe, Asia Pacific, Latin America, the Middle East, and Africa. The region's highest CAGR can be attributed to rising adoption of connected diabetes management devices, rising adoption of diabetes management and obesity apps, rising demand for technologically advanced solutions, payer acceptance of digital diabetes solutions, government initiatives to promote digital health, and rising awareness of self-diabetes management.
Need any customization research on Digital Diabetes Management Market - Enquiry Now
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
The major key players are Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd., Bayer AG, Lifescan, Inc, Dexcom, Inc, Sanofi, Insulet Corporation, Ascensia Diabetes Care Holdings Ag, B Braun Melsungen AG and others.
Dexcom: In February 2023,Dexcom announced the Dexcom G7 CGM device in the United States and plans to market it in Europe and Asia Pacific in the first quarter of 2024.
Abbott Laboratories: In October2022, Abbott Laboratories has released the Freestyle Libre 3 CGM gadget on a global scale.
| Report Attributes | Details |
| Market Size in 2023 | US$ 18.8 Bn |
| Market Size by 2032 | US$ 59.7 Bn |
| CAGR | CAGR of 13.7% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Smart Glucose Meter, Continuous Blood Glucose Monitoring System, Smart Insulin Pens, Smart Insulin Pumps, Apps (Digital Diabetes Management Apps, Weight & Diet Management Apps)) • By Type (Wearable Devices, Handheld Devices) • By End Use (Hospitals, Home settings, Diagnostic Centers) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd., Bayer AG, Lifescan, Inc, Dexcom, Inc, Sanofi, Insulet Corporation, Ascensia Diabetes Care Holdings Ag, B Braun Melsungen AG |
| Key Drivers | • Artificial Intelligence Is Making Its Way Into Diabetes Care Devices |
| Market Restraints | • High equipment costs and a lack of reimbursement in poor countries. |
Ans: The Digital Diabetes Management Market is expected to grow at 13.7% CAGR from 2024 to 2032.
Ans: According to our analysis, the Digital Diabetes Management Market is anticipated to reach USD 59.7 billion By 2032.
Ans: The leading participants in the,Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd., Bayer AG, Lifescan, Inc, Dexcom, Inc, Sanofi, Insulet Corporation, Ascensia Diabetes Care Holdings Ag, B Braun Melsungen AG.
Ans: Growing technical improvements and rising FDA approval for innovative solutions are key factors driving the digital diabetes management market's expansion.
Ans: Yes, you may request customization based on your company's needs.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine- Russia war
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Digital Diabetes Management Market, By Product
8.1 Smart Glucose Meter
8.2 Continuous Blood Glucose Monitoring System
8.3 Smart Insulin Pens
8.4 Smart Insulin Pumps
8.5 Apps
8.5.1 Digital Diabetes Management Apps
8.5.2 Weight & Diet Management Apps
9. Digital Diabetes Management Market,By Type
9.1 Wearable Devices
9.2 Handheld Devices
10. Digital Diabetes Management Market, By End Use
10.1 Hospitals
10.2 Home settings
10.3 Diagnostic Centers
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Digital Diabetes Management Market by country
11.2.2North America Digital Diabetes Management Market by Product
11.2.3 North America Digital Diabetes Management Market by Type
11.2.4 North America Digital Diabetes Management Market by End-user
11.2.5 USA
11.2.5.1 USA Digital Diabetes Management Market by Product
11.2.5.2 USA Digital Diabetes Management Market by Type
11.2.5.3 USA Digital Diabetes Management Market by End-user
11.2.6 Canada
11.2.6.1 Canada Digital Diabetes Management Market by Product
11.2.6.2 Canada Digital Diabetes Management Market by Type
11.2.6.3 Canada Digital Diabetes Management Market by End-user
11.2.7 Mexico
11.2.7.1 Mexico Digital Diabetes Management Market by Product
11.2.7.2 Mexico Digital Diabetes Management Market by Type
11.2.7.3 Mexico Digital Diabetes Management Market by End-user
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Eastern Europe Digital Diabetes Management Market by country
11.3.1.2 Eastern Europe Digital Diabetes Management Market by Product
11.3.1.3 Eastern Europe Digital Diabetes Management Market by Type
11.3.1.4 Eastern Europe Digital Diabetes Management Market by End-user
11.3.1.5 Poland
11.3.1.5.1 Poland Digital Diabetes Management Market by Product
11.3.1.5.2 Poland Digital Diabetes Management Market by Type
11.3.1.5.3 Poland Digital Diabetes Management Market by End-user
11.3.1.6 Romania
11.3.1.6.1 Romania Digital Diabetes Management Market by Product
11.3.1.6.2 Romania Digital Diabetes Management Market by Type
11.3.1.6.4 Romania Digital Diabetes Management Market by End-user
11.3.1.7 Turkey
11.3.1.7.1 Turkey Digital Diabetes Management Market by Product
11.3.1.7.2 Turkey Digital Diabetes Management Market by Type
11.3.1.7.3 Turkey Digital Diabetes Management Market by End-user
11.3.1.8 Rest of Eastern Europe
11.3.1.8.1 Rest of Eastern Europe Digital Diabetes Management Market by Product
11.3.1.8.2 Rest of Eastern Europe Digital Diabetes Management Market by Type
11.3.1.8.3 Rest of Eastern Europe Digital Diabetes Management Market by End-user
11.3.2 Western Europe
11.3.2.1 Western Europe Digital Diabetes Management Market by Product
11.3.2.2 Western Europe Digital Diabetes Management Market by Type
11.3.2.3 Western Europe Digital Diabetes Management Market by End-user
11.3.2.4 Germany
11.3.2.4.1 Germany Digital Diabetes Management Market by Product
11.3.2.4.2 Germany Digital Diabetes Management Market by Type
11.3.2.4.3 Germany Digital Diabetes Management Market by End-user
11.3.2.5 France
11.3.2.5.1 France Digital Diabetes Management Market by Product
11.3.2.5.2 France Digital Diabetes Management Market by Type
11.3.2.5.3 France Digital Diabetes Management Market by End-user
11.3.2.6 UK
11.3.2.6.1 UK Digital Diabetes Management Market by Product
11.3.2.6.2 UK Digital Diabetes Management Market by Type
11.3.2.6.3 UK Digital Diabetes Management Market by End-user
11.3.2.7 Italy
11.3.2.7.1 Italy Digital Diabetes Management Market by Product
11.3.2.7.2 Italy Digital Diabetes Management Market by Type
11.3.2.7.3 Italy Digital Diabetes Management Market by End-user
11.3.2.8 Spain
11.3.2.8.1 Spain Digital Diabetes Management Market by Product
11.3.2.8.2 Spain Digital Diabetes Management Market by Type
11.3.2.8.3 Spain Digital Diabetes Management Market by End-user
11.3.2.9 Netherlands
11.3.2.9.1 Netherlands Digital Diabetes Management Market by Product
11.3.2.9.2 Netherlands Digital Diabetes Management Market by Type
11.3.2.9.3 Netherlands Digital Diabetes Management Market by End-user
11.3.2.10 Switzerland
11.3.2.10.1 Switzerland Digital Diabetes Management Market by Product
11.3.2.10.2 Switzerland Digital Diabetes Management Market by Type
11.3.2.10.3 Switzerland Digital Diabetes Management Market by End-user
11.3.2.11.1 Austria
11.3.2.11.2 Austria Digital Diabetes Management Market by Product
11.3.2.11.3 Austria Digital Diabetes Management Market by Type
11.3.2.11.4 Austria Digital Diabetes Management Market by End-user
11.3.2.12 Rest of Western Europe
11.3.2.12.1 Rest of Western Europe Digital Diabetes Management Market by Product
11.3.2.12.2 Rest of Western Europe Digital Diabetes Management Market by Type
11.3.2.12.3 Rest of Western Europe Digital Diabetes Management Market by End-user
11.4 Asia-Pacific
11.4.1 Asia-Pacific Digital Diabetes Management Market by country
11.4.2 Asia-Pacific Digital Diabetes Management Market by Product
11.4.3 Asia-Pacific Digital Diabetes Management Market by Type
11.4.4 Asia-Pacific Digital Diabetes Management Market by End-user
11.4.5 China
11.4.5.1 China Digital Diabetes Management Market by Product
11.4.5.2 China Digital Diabetes Management Market by Type
11.4.5.3 China Digital Diabetes Management Market End-user
11.4.6 India
11.4.6.1 India Digital Diabetes Management Market by Product
11.4.6.2 India Digital Diabetes Management Market by Type
11.4.6.3 India Digital Diabetes Management Market by End-user
11.4.7 Japan
11.4.7.1 Japan Digital Diabetes Management Market by Product
11.4.7.2 Japan Digital Diabetes Management Market by Type
11.4.7.3 Japan Digital Diabetes Management Market by End-user
11.4.8 South Korea
11.4.8.1 South Korea Digital Diabetes Management Market by Product
11.4.8.2 South Korea Digital Diabetes Management Market by Type
11.4.8.3 South Korea Digital Diabetes Management Market by End-user
11.4.9 Vietnam
11.4.9.1 Vietnam Digital Diabetes Management Market by Product
11.4.9.2 Vietnam Digital Diabetes Management Market by Type
11.4.9.3 Vietnam Digital Diabetes Management Market by End-user
11.4.10 Singapore
11.4.10.1 Singapore Digital Diabetes Management Market by Product
11.4.10.2 Singapore Digital Diabetes Management Market by Type
11.4.10.3 Singapore Digital Diabetes Management Market by End-user
11.4.11 Australia
11.4.11.1 Australia Digital Diabetes Management Market by Product
11.4.11.2 Australia Digital Diabetes Management Market by Type
11.4.11.3 Australia Digital Diabetes Management Market by End-user
11.4.12 Rest of Asia-Pacific
11.4.12.1 Rest of Asia-Pacific Digital Diabetes Management Market by Product
11.4.12.2 Rest of Asia-Pacific Digital Diabetes Management Market by Type
11.4.12.3 Rest of Asia-Pacific Digital Diabetes Management Market by End-user
11.5 Middle East & Africa
11.5.1 Middle East
11.5.1.1 Middle East Digital Diabetes Management Market by country
11.5.1.2 Middle East Digital Diabetes Management Market by Product
11.5.1.3 Middle East Digital Diabetes Management Market by Type
11.5.1.4 Middle East Digital Diabetes Management Market by End-user
11.5.1.5 UAE
11.5.1.5.1 UAE Digital Diabetes Management Market by Product
11.5.1.5.2 UAE Digital Diabetes Management Market by Type
11.5.1.5.3 UAE Digital Diabetes Management Market by End-user
11.5.1.6 Egypt
11.5.1.6.1 Egypt Digital Diabetes Management Market by Product
11.5.1.6.2 Egypt Digital Diabetes Management Market by Type
11.5.1.6.3 Egypt Digital Diabetes Management Market by End-user
11.5.1.7 Saudi Arabia
11.5.1.7.1 Saudi Arabia Digital Diabetes Management Market by Product
11.5.1.7.2 Saudi Arabia Digital Diabetes Management Market by Type
11.5.1.7.3 Saudi Arabia Digital Diabetes Management Market by End-user
11.5.1.8 Qatar
11.5.1.8.1 Qatar Digital Diabetes Management Market by Product
11.5.1.8.2 Qatar Digital Diabetes Management Market by Type
11.5.1.8.3 Qatar Digital Diabetes Management Market by End-user
11.5.1.9 Rest of Middle East
11.5.1.9.1 Rest of Middle East Digital Diabetes Management Market by Product
11.5.1.9.2 Rest of Middle East Digital Diabetes Management Market by Type
11.5.1.9.3 Rest of Middle East Digital Diabetes Management Market by End-user
11.5.2 Africa
11.5.2.1 Africa Digital Diabetes Management Market by country
11.5.2.2 Africa Digital Diabetes Management Market by Product
11.5.2.3 Africa Digital Diabetes Management Market by Type
11.5.2.4 Africa Digital Diabetes Management Market by End-user
11.5.2.5 Nigeria
11.5.2.5.1 Nigeria Digital Diabetes Management Market by Product
11.5.2.5.2 Nigeria Digital Diabetes Management Market by Type
11.5.2.5.3 Nigeria Digital Diabetes Management Market by End-user
11.5.2.6 South Africa
11.5.2.6.1 South Africa Digital Diabetes Management Market by Product
11.5.2.6.2 South Africa Digital Diabetes Management Market by Type
11.5.2.6.3 South Africa Digital Diabetes Management Market by End-user
11.5.2.7 Rest of Africa
11.5.2.7.1 Rest of Africa Digital Diabetes Management Market by Product
11.5.2.7.2 Rest of Africa Digital Diabetes Management Market by Type
11.5.2.7.3 Rest of Africa Digital Diabetes Management Market by End-user
11.6 Latin America
11.6.1 Latin America Digital Diabetes Management Market by country
11.6.2 Latin America Digital Diabetes Management Market by Product
11.6.3 Latin America Digital Diabetes Management Market by Type
11.6.4 Latin America Digital Diabetes Management Market by End-user
11.6.5 Brazil
11.6.5.1 Brazil America Wheelchair by Product
11.6.5.2 Brazil America Wheelchair by Type
11.6.5.3 Brazil America Wheelchair by End-user
11.6.6 Argentina
11.6.6.1 Argentina America Wheelchair by Product
11.6.6.2 Argentina America Wheelchair by Type
11.6.6.3 Argentina America Wheelchair by End-user
11.6.7 Colombia
11.6.7.1 Colombia America Wheelchair by Product
11.6.7.2 Colombia America Wheelchair by Type
11.6.7.3 Colombia America Wheelchair by End-user
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Wheelchair by Product
11.6.8.2 Rest of Latin America Wheelchair by Type
11.6.8.3 Rest of Latin America Wheelchair by End-user
12 Company profile
12.1 Abbott Laboratories
12.1.1 Company Overview
12.1.2 Financials
12.1.3 Product/Services/Offerings
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Medtronic plc.
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Product/Services/Offerings
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 F. Hoffmann-La Roche Ltd.,
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Product/Services/Offerings
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Bayer AG,
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Product/Services/Offerings
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Lifescan, Inc
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Product/Services/Offerings
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Dexcom, Inc.
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Product/Services/Offerings
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Sanofi
12.7.1 Company Overview
12.7.2 Financials
12.7.3 Product/Services/Offerings
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Insulet Corporation.
12.8.2 Financials
12.8.3 Product/Services/Offerings
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Ascensia Diabetes Care Holdings Ag.
12.9.1 Company Overview
12.9.2 Financials
12.9.3 Product/Services/Offerings
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 B Braun Melsungen AG
12.10.1 Company Overview
12.10.2 Financials
12.10.3 Product/Services/Offerings
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Bench marking
13.2 Market Share Analysis
13.3 Recent Developments
13.3.1 Industry News
13.3.2 Company News
13.3.3 Mergers & Acquisitions
14. Use Case and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Pharmaceutical Excipients Market Size was valued at USD 9.09 billion in 2023 and is expected to reach USD 14.52 billion by 2031, and grow at a CAGR of 6.02% over the forecast period 2024-2031.
The Clinical Workflow Solutions Market Size was valued at USD 11.07 billion in 2023 and will reach $32.71 billion by 2032, growing at a CAGR of 12.81% over the forecast period of 2024-2032.
The Demineralized Bone Matrix (DBM) Market Size was valued at USD 1.29 billion in 2023 and is projected to reach USD 2.18 billion by 2032 with a growing CAGR of 5.98% Over the Forecast Period of 2024-2032.
The Healthcare Biometrics Market Size was valued at USD 23.05 billion in 2023 and is expected to reach USD 136.02 billion by 2032 and grow at a CAGR of 21.8% over the forecast period 2024-2032.
The Conversational AI in Healthcare Market Size was valued at USD 10.80 Billion in 2023 and is expected to reach USD 80.50 Billion by 2032 and grow at a CAGR of 25.02% over the forecast period 2024-2032.
The Digital Clinical Trials Market was valued at USD 8.70 Bn in 2023 and is expected to reach at $13.86 Bn in 2031 and grow at a CAGR of 6 % by 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
